Assessment of New Molecular Entities Approved for Cancer Treatment in 2020.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34047795.
- Also identified by DOI 10.1001/jamanetworkopen.2021.12558 and PMC identifier 8164099.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study of all hematology/oncology drugs approved by the US Food and Drug Administration in 2020 assesses the functioning of the drug approval process following disruptions related to the COVID-19 pandemic.
Medical subject headings
- Antineoplastic Agents
- Drug Approval
- Neoplasms